The Gillett Health Podcast Is this the BEST weight loss peptide?
Feb 24, 2026
They break down new Cagrisema trial results and how it stacks up against tirzepatide for weight loss. They explore amylin biology and why amylin replacement matters for metabolism. They debate combination therapies, dosing strategies, and real-world side effects. They discuss body composition, protein and resistance training in trials, and what an ideal future molecule might look like.
AI Snips
Chapters
Transcript
Episode notes
Cagri Sema Adds Amylin To GLP-1 For Weight Loss
- Cagri-Sema combines semaglutide (a GLP-1) with cagrelinotide (an amylin agonist) and showed ~23% weight loss at 84 weeks, slightly behind tirzepatide's results.
- Kyle Gillett, MD explains amylin replacement addresses beta cell loss in diabetes and complements GLP-1s by targeting a different pancreatic peptide pathway.
Body Composition May Outweigh Raw Weight Loss
- Body composition and metabolic outcomes may matter more than absolute weight loss when comparing incretin-amylin combos to tirzepatide.
- Kyle Gillett, MD suggests the amylin combo could preserve muscle, improve insulin sensitivity, and affect IGF-1 differently despite slightly less weight loss.
Don't Default To Max GLP-1 Doses For Weight Loss
- Avoid automatically using max GLP-1 doses for non-diabetic weight loss; lower doses plus lifestyle yield fewer side effects and are more sustainable.
- Kyle Gillett, MD recommends tailoring dose to need and preserving lifestyle changes to ease discontinuation and reduce dose-dependent adverse effects.